Loading...
The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
AT13387 is an orally bioavailable clinical candidate developed to inhibit theheat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, avoids stringent reaction conditions and...
Na minha lista:
| Udgivet i: | Synth Commun |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577423/ https://ncbi.nlm.nih.gov/pubmed/33093687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/00397911.2019.1602654 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|